Paper Details

  1. Home
  2. Paper Details

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.

Author: BeutelsP, ChenC, DirmesropianS, MacIntyreC R, McIntyreP, MenziesR, NewallA T, ReyesJ F, WoodJ G

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the replacement of a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) in older Australian adults.
Paper Details　
Original Abstract of the Article :
The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been funded under the Australia National Immunisation Program (NIP) since January 2005 for those aged >65years and other risk groups. In 2016, PCV13 was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) as a replacement fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2017.06.085

データ提供：米国国立医学図書館（NLM）

Pneumococcal Vaccination for Older Australians: A Cost-Effective Approach

Pneumococcal disease, a bacterial infection, can be serious, especially for older adults. This study examines the cost-effectiveness of a new 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. The researchers compared PCV13 to the existing 23-valent pneumococcal polysaccharide vaccine (PPV23) which has been used for years.

Protecting Against Pneumococcal Disease: An Economic and Health Perspective

The findings suggest that PCV13 is a cost-effective alternative to PPV23 for older Australians. The study found that PCV13 provides better protection against pneumococcal disease, particularly against common strains that can lead to serious illness. The researchers also found that PCV13 could lead to cost savings in the long run by reducing hospitalizations and other healthcare costs.

Staying Healthy in Your Golden Years: Vaccines Play a Vital Role

This study highlights the importance of vaccination in maintaining good health, particularly for older adults. It underscores the value of using effective and cost-effective vaccines to protect against preventable diseases like pneumococcal disease. It's a reminder that preventive measures can play a significant role in promoting healthy aging.

Dr.Camel's Conclusion

This study provides valuable evidence for the cost-effectiveness of PCV13 in older Australians. It's a reminder that investing in preventive measures, such as vaccination, can not only improve health outcomes but also save resources in the long run. Just as a camel prepares for a long journey across the desert, we should prepare for a healthy and fulfilling later life by taking advantage of available preventive measures like vaccination. It's a wise investment in our well-being, ensuring a smoother and more comfortable journey through the years.
Date :
  1. Date Completed 2018-03-19
  2. Date Revised 2018-04-02
Further Info :

Pubmed ID

28693751

DOI: Digital Object Identifier

10.1016/j.vaccine.2017.06.085

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.